الفهرس 
Cancer ColonOnly 14 pages are availabe for public view
 |  | from | 149 |  |  |
| | | from | 149 | | |
Abstract
Summary Colon cancer is the fourth largest cancer in the nation and 8th largest cancer in the rectum. Together the third most diagnosed type of cancer in the world is CRCs, which account for 11 percent of all diagnosis of cancer. The CRC determination is focused on clinical, serological and endoscopic observations. Non-invasive, cost-effective and convenient to use clinical and serological examinations. Hemoglobin antibodies for detecting secret blood in the stool are used by the FIT. Early iterations of this test did not provide as highly sensitive cancer identification as new, highly sensitive versions on the market since over 10 years. FIT is more realistic than gFOBT, as no food restrictions are necessary. Pyruvatekinase is a crucial enzyme in the glucose metabolism and is contained in organ specific isoforms that transforms phosphoenolpyruvate into pyruvate. M2-PK has a strong affinity with phosphoenolpyruvate in normally developing cells, mostly tetrameric. In comparison, it is normally dimeric and low affinity to phosphoenolpyruvate to the M2PK isoenzyme present in tumor cells. A direct association between M2-PK and separate oncoprotein is the product of dissociation of tetrameric form from dimeric structure in tumor cells. The dimeric type of M2PK has also been dubbed M2PK tumour. Tumor M2-PK is readily released from tumor cells and can be detected in quantitative measurement in body fluids owing to its low affinity to phosphoenolpyruvate. The aim of this analysis is to assess the sensitivity in high risk or symptomatic populations of fecal tumor M2 pyruvate kinase (M2PK).